Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Shareholder Meeting (October 2020)
11 slides from Oncosil Medical's shareholder meeting presentation, Oct 20, 2020
Slide 1: CEO AGM Presentation: Advancing Pancreatic cancer treatment
For personal use only ASX.OSL CEO AGM Presentation Advancing Pancreatic cancer treatment Transforming the prognosis 20 October 2020
Slide 2: Commercialising a breakthrough implantable radiotherapy treatment for pancreatic cancer
For personal use only Commercialising a breakthrough implantable radiotherapy treatment for pancreatic cancer 3
Slide 3: Key Highlights
Key Highlights For personal use only Europe Continue to progress critical launch preparation activities – we remain on track for first LAPC sales in 2020 ASEAN / APAC Targeting first sales in the region in 2020 - approved in New Zealand, Singapore and LAPC Malaysia; awaiting outcomes of registration
Slide 4: Update on key 2020 objectives
Update on key 2020 objectives For personal use only List of milestones achieved since CE Mark in April 2020 Upcoming catalysts Completed ~$19m placement and entitlement offer to fund commercialisation globally • Expected first sale in UK/EU – 2H Appointment of Nigel Lange (ex Sirtex Europe CEO) to d
Slide 5: Treating pancreatic cancer is challenging and difficult
Treating pancreatic cancer is challenging and difficult For personal use only Existing treatments for pancreatic cancer are ineffective... ...resulting in very poor survival rates1 Late diagnosis • Symptoms often unnoticed until cancer has metastasised Sub-optimal current standard of care ~8.5 month
Slide 6: The OncoSil device provides a unique and effective solution
The OncoSil™ device provides a unique and effective solution Radiation therapy delivered directly into the tumour For personal use only OncoSil™ has clinically proven to prolong median overall survival in LAPC patients Effectively doubled ~16 months Reduction in the risk of death compared to length
Slide 7: Updated analysis on resected cohort illustrates potential to convert inoperable patients
Updated analysis on resected cohort illustrates potential to convert inoperable patients to operable status For personal use only 42 patients treated 10 underwent surgery 6 remain alive with >26 months survival post-treatment • 42 patients with unresectable, • 14 were sufficiently downstaged to • On
Slide 8: Clear market opportunity for OncoSil to become standard of care in LAPC
Clear market opportunity for OncoSil to become standard of care in LAPC There are more than 40k locally advanced pancreatic cancer (LAPC) cases p.a. in EU & UK 1,2 For personal use only Disease prognosis Current treatment OncoSil solution Future OncoSil™ could be used to downstage tumours focus 15%
Slide 9: European commercialisation update
European commercialisation update For personal use only ✓ 9 direct OncoSil sales force and training resource in place in UK, Germany, Italy, Benelux Sales force and recruitment ✓ Sales force recruitment continues ✓ Central Radio-pharmacy (CRP) established & contracted to service up 15 hospital in th
Slide 10: Important notice
Important notice For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this P
Slide 11: Daniel Kenny, CEO & Managing Director
For personal use only Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +61 2 9223 3344 F: +61 2 9252 3988